ArticleOpen forum infectious diseases2022

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients.

Navina K Birk et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.